Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Malignant Melanoma

  Free Subscription

Articles published in Br J Cancer

Retrieve available abstracts of 43 articles:
HTML format

Single Articles

    July 2022
  1. LI Y, Wang Q, Chen Y, Zhao L, et al
    Somatic mutations in DCC are associated with genomic instability and favourable outcomes in melanoma patients treated with immune checkpoint inhibitors.
    Br J Cancer. 2022 Jul 23. pii: 10.1038/s41416-022-01921.
    PubMed     Abstract available

    June 2022
  2. BARCELO C, Siso P, de la Rosa I, Megino-Luque C, et al
    M-CSF as a therapeutic target in BRAF(V600E) melanoma resistant to BRAF inhibitors.
    Br J Cancer. 2022 Jun 20. pii: 10.1038/s41416-022-01886.
    PubMed     Abstract available

  3. BREST P, Refae S, Mograbi B, Ferrero JM, et al
    Checkpoint inhibitors in a marriage: consented or arranged?
    Br J Cancer. 2022;126:1834-1836.
    PubMed     Abstract available

    April 2022
  4. LUNDBERG A, Li B, Li R
    B cell-related gene signature and cancer immunotherapy response.
    Br J Cancer. 2022;126:899-906.
    PubMed     Abstract available

    March 2022
  5. RAMTOHUL T, Cohen A, Rodrigues M, Piperno-Neumann S, et al
    Tumour growth rate improves tumour assessment and first-line systemic treatment decision-making for immunotherapy in patients with liver metastatic uveal melanoma.
    Br J Cancer. 2022 Mar 26. pii: 10.1038/s41416-022-01793.
    PubMed     Abstract available

  6. KUMAR PR, Saad M, Hellmich C, Mistry JJ, et al
    PGC-1alpha induced mitochondrial biogenesis in stromal cells underpins mitochondrial transfer to melanoma.
    Br J Cancer. 2022 Mar 26. pii: 10.1038/s41416-022-01783.
    PubMed     Abstract available

  7. WOOF VG, Lee RJ, Lorigan P, French DP, et al
    Circulating tumour DNA monitoring and early treatment for relapse: views from patients with early-stage melanoma.
    Br J Cancer. 2022 Mar 17. pii: 10.1038/s41416-022-01766.
    PubMed     Abstract available

  8. VAN BREESCHOTEN J, Wouters MWJM, Hilarius DL, Haanen JB, et al
    Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis.
    Br J Cancer. 2022 Mar 7. pii: 10.1038/s41416-022-01772.

    February 2022
  9. BEASLEY AB, Chen FK, Isaacs TW, Gray ES, et al
    Future perspectives of uveal melanoma blood based biomarkers.
    Br J Cancer. 2022 Feb 21. pii: 10.1038/s41416-022-01723.
    PubMed     Abstract available

    November 2021
  10. HAMIS SJ, Kapelyukh Y, McLaren A, Henderson CJ, et al
    Quantifying ERK activity in response to inhibition of the BRAFV600E-MEK-ERK cascade using mathematical modelling.
    Br J Cancer. 2021;125:1552-1560.
    PubMed     Abstract available

    October 2021
    Checkpoint blocker induced autoimmunity as an indicator for tumour efficacy in melanoma.
    Br J Cancer. 2021 Oct 25. pii: 10.1038/s41416-021-01390.
    PubMed     Abstract available

    August 2021
  12. MARSAVELA G, McEvoy AC, Pereira MR, Reid AL, et al
    Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression.
    Br J Cancer. 2021 Aug 9. pii: 10.1038/s41416-021-01507.
    PubMed     Abstract available

    July 2021
  13. BOUCHEREAU S, Chaplain L, Fort M, Beauchet A, et al
    Impact of prior treatment with immune checkpoint inhibitors on dacarbazine efficacy in metastatic melanoma.
    Br J Cancer. 2021 Jul 14. pii: 10.1038/s41416-021-01486.
    PubMed     Abstract available

    June 2021
  14. MAIQUES O, Fanshawe B, Crosas-Molist E, Rodriguez-Hernandez I, et al
    A preclinical pipeline to evaluate migrastatics as therapeutic agents in metastatic melanoma.
    Br J Cancer. 2021 Jun 25. pii: 10.1038/s41416-021-01442.
    PubMed     Abstract available

    May 2021
  15. WEBER A, Leitzmann MF, Sedlmeier AM, Baurecht H, et al
    Association between physical activity, grip strength and sedentary behaviour with incidence of malignant melanoma: results from the UK Biobank.
    Br J Cancer. 2021 May 31. pii: 10.1038/s41416-021-01443.
    PubMed     Abstract available

    April 2021
  16. DHOMEN N, Mundra PA, Marais R
    Sunglasses to hide behind may also prevent melanoma of the eyes.
    Br J Cancer. 2021 Apr 6. pii: 10.1038/s41416-021-01343.
    PubMed     Abstract available

  17. WANG H, Elsheikh M, Gilmour K, Cohen V, et al
    Impact of COVID-19 pandemic on eye cancer care in United Kingdom.
    Br J Cancer. 2021;124:1357-1360.
    PubMed     Abstract available

    March 2021
  18. VAN BREESCHOTEN J, Wouters MWJM, Hilarius DL, Haanen JB, et al
    Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-021-01312.

  19. YE W, Olsson-Brown A, Watson RA, Cheung VTF, et al
    Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-021-01310.
    PubMed     Abstract available

  20. YAO S, Janku F, Subbiah V, Stewart J, et al
    Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies.
    Br J Cancer. 2021 Mar 5. pii: 10.1038/s41416-020-01230.
    PubMed     Abstract available

  21. KATO R, Haratani K, Hayashi H, Sakai K, et al
    Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts.
    Br J Cancer. 2021;124:914-924.
    PubMed     Abstract available

    February 2021
  22. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
    Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
    PubMed     Abstract available

    January 2021
  23. VAN BREESCHOTEN J, Wouters MWJM, Hilarius DL, Haanen JB, et al
    First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis.
    Br J Cancer. 2021 Jan 26. pii: 10.1038/s41416-020-01229.
    PubMed     Abstract available

    December 2020
  24. AMERATUNGA M, Brana I, Bono P, Postel-Vinay S, et al
    First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
    Br J Cancer. 2020;123:1730-1736.
    PubMed     Abstract available

    November 2020
  25. KUMAR PR, Moore JA, Bowles KM, Rushworth SA, et al
    Mitochondrial oxidative phosphorylation in cutaneous melanoma.
    Br J Cancer. 2020 Nov 18. pii: 10.1038/s41416-020-01159.
    PubMed     Abstract available

  26. SMITH AJ, Lambert PC, Rutherford MJ
    Understanding the impact of sex and stage differences on melanoma cancer patient survival: a SEER-based study.
    Br J Cancer. 2020 Nov 4. pii: 10.1038/s41416-020-01144.
    PubMed     Abstract available

    October 2020
  27. BHAVE P, Pallan L, Long GV, Menzies AM, et al
    Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.
    Br J Cancer. 2020 Oct 22. pii: 10.1038/s41416-020-01121.
    PubMed     Abstract available

  28. PAMIDIMUKKALA N, Puts GS, Kathryn Leonard M, Snyder D, et al
    Nme1 and Nme2 genes exert metastasis-suppressor activities in a genetically engineered mouse model of UV-induced melanoma.
    Br J Cancer. 2020 Oct 7. pii: 10.1038/s41416-020-01096.
    PubMed     Abstract available

  29. RABBIE R, Ferguson P, Wong K, Couturier DL, et al
    The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence.
    Br J Cancer. 2020 Oct 7. pii: 10.1038/s41416-020-01090.
    PubMed     Abstract available

    August 2020
  30. TREMBLE LF, McCabe M, Walker SP, McCarthy S, et al
    Differential association of CD68(+) and CD163(+) macrophages with macrophage enzymes, whole tumour gene expression and overall survival in advanced melanoma.
    Br J Cancer. 2020 Aug 26. pii: 10.1038/s41416-020-01037.
    PubMed     Abstract available

  31. ALMEIDA RR, Vieira RS, Castoldi A, Terra FF, et al
    Host dysbiosis negatively impacts IL-9-producing T-cell differentiation and antitumour immunity.
    Br J Cancer. 2020;123:534-541.
    PubMed     Abstract available

    July 2020
  32. MIDDLETON MR, Hoeller C, Michielin O, Robert C, et al
    Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives.
    Br J Cancer. 2020 Jul 27. pii: 10.1038/s41416-020-0994.
    PubMed     Abstract available

  33. CHEUNG VTF, Gupta T, Olsson-Brown A, Subramanian S, et al
    Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?
    Br J Cancer. 2020;123:207-215.
    PubMed     Abstract available

    April 2020
  34. TROIANI T, Giunta EF, Tufano M, Vigorito V, et al
    Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients.
    Br J Cancer. 2020 Apr 22. pii: 10.1038/s41416-020-0840.
    PubMed     Abstract available

  35. MCNEILLIS R, Greystoke A, Walton J, Bacon C, et al
    A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965.
    Br J Cancer. 2020;122:1141-1145.
    PubMed     Abstract available

    February 2020
  36. GRANADOS K, Huser L, Federico A, Sachindra S, et al
    T-type calcium channel inhibition restores sensitivity to MAPK inhibitors in de-differentiated and adaptive melanoma cells.
    Br J Cancer. 2020 Feb 17. pii: 10.1038/s41416-020-0751.
    PubMed     Abstract available

  37. SPAIN L, Larkin J, Turajlic S
    New survival standards for advanced melanoma.
    Br J Cancer. 2020 Feb 17. pii: 10.1038/s41416-020-0738.

  38. AYA-BONILLA CA, Morici M, Hong X, McEvoy AC, et al
    Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells.
    Br J Cancer. 2020 Feb 10. pii: 10.1038/s41416-020-0750.
    PubMed     Abstract available

    January 2020
  39. TIAGO M, Capparelli C, Erkes DA, Purwin TJ, et al
    Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma.
    Br J Cancer. 2020 Jan 14. pii: 10.1038/s41416-019-0724.
    PubMed     Abstract available

    December 2019
  40. ICE RJ, Chen M, Sidorov M, Le Ho T, et al
    Drug responses are conserved across patient-derived xenograft models of melanoma leading to identification of novel drug combination therapies.
    Br J Cancer. 2019 Dec 20. pii: 10.1038/s41416-019-0696.
    PubMed     Abstract available

  41. GUPTA A, Towers C, Willenbrock F, Brant R, et al
    Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma.
    Br J Cancer. 2019 Dec 16. pii: 10.1038/s41416-019-0673.
    PubMed     Abstract available

  42. DELGADO-GONI T, Galobart TC, Wantuch S, Normantaite D, et al
    Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells.
    Br J Cancer. 2019 Dec 10. pii: 10.1038/s41416-019-0628.
    PubMed     Abstract available

    February 2019
  43. LIU C, He H, Li X, Su MA, et al
    Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy.
    Br J Cancer. 2019;120:346-355.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.